Medicine & Life Sciences
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
20%
Acute Myeloid Leukemia
100%
Acute Promyelocytic Leukemia
11%
Allogeneic Cells
10%
Azacitidine
14%
B-Cell Chronic Lymphocytic Leukemia
26%
Blast Crisis
13%
blinatumomab
14%
Bone Marrow
16%
Chromosome Aberrations
9%
Clofarabine
11%
Cyclophosphamide
10%
Cytarabine
34%
Cytogenetics
36%
Dasatinib
20%
Decitabine
20%
Drug Therapy
19%
fludarabine
20%
GATA2 Deficiency
14%
Hematologic Neoplasms
13%
Idarubicin
11%
Imatinib Mesylate
63%
INCB018424
10%
Inotuzumab Ozogamicin
15%
Interferon-alpha
7%
Interferons
11%
Leukemia
38%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
96%
Leukemia, Myeloid, Chronic Phase
44%
Leukemia, Myelomonocytic, Chronic
14%
Mutation
22%
Myelodysplastic Syndromes
52%
Neoplasms
14%
Philadelphia Chromosome
43%
Phosphotransferases
8%
ponatinib
11%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
63%
Primary Myelofibrosis
19%
Progression-Free Survival
9%
Protein-Tyrosine Kinases
36%
Recurrence
11%
Residual Neoplasm
8%
Rituximab
8%
Safety
10%
Salvage Therapy
9%
Stem Cell Transplantation
11%
Survival
37%
Therapeutics
32%
venetoclax
18%
Vincristine
9%